- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Surya Singh, MD, Explains How Biosimilar Education Has Reduced Provider Doubt
Surya Singh, MD discusses how education efforts have reduced providers’ doubts surrounding the similarity between biosimilars and their reference products at the March 2020 FDA/Federal Trade Commission workshop on anticompetitive practices.
Surya Singh, MD, is the president of Singh Healthcare Advisors.
Transcript:
Have education efforts reduced provider doubt regarding the similarity of biosimilars and their reference products?
I think that the educational component of biosimilar uptake had a slow start 5 years ago, but has really accelerated now [that we’ve] gotten over what I'll refer to as the educational threshold for providers. So, if the question is, "Is there still lingering doubt in the minds of providers on whether or not a biosimilar is sufficiently comparable to the reference product in order for them to safely prescribe it and have their patient use it?" the answer to that is I don't think there's lingering doubt. I think most of the doubt that was present in the earlier days following the first biosimilar approvals has really been taken care of or eliminated based on the educational efforts that were undertaken by a number of different groups, but also by experience. So, they've gained experience with biosimilar products and realized what a lot of people were saying at the outset: The batch-to-batch variability between the reference product being produced in the same facility was as great as it is between a biosimilar product and the reference product. I think experience has helped a lot of clinicians who had some doubt at the outset get over that doubt. So, I would contend that if there is any lingering doubt that is impeding biosimilar uptake, it pales in comparison to some of the economic considerations that are at play in the market.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
